Jeannet M
Schweiz Med Wochenschr. 1975 Jun 14;105(24):780-2.
Anti-HL-A alloimunization has increased in frequency, particularly in patients with acute leukemia, since platelet and leukocyte transfusions have been systematically used for the prevention of hemorrhages and infections during the induction phase of chemotherapy. Although a systematic prevention of anti-HL-A immunization is not yet feasible in most cases, the selection of HL-A compatible donors can restore the efficiency of platelet and leukocyte transfusions even if alloimmunization is very severe. Compatible donors can sometimes be found in the patient's family, but the existence of a panel of HL-A typed blood donors will considerably facilitate the efficiency of the hematological supportive care of patients with leukemia and with bone-marrow aplasia of other origins.
自系统应用血小板和白细胞输注以预防化疗诱导期出血和感染以来，抗人白细胞抗原（HL-A）同种免疫的发生率有所增加，尤其是在急性白血病患者中。尽管在大多数情况下，系统性预防抗HL-A免疫尚不可行，但即使同种免疫非常严重，选择HL-A相容供者也可恢复血小板和白细胞输注的疗效。有时可在患者家族中找到相容供者，但一组HL-A分型的献血者的存在将极大地提高白血病患者以及其他原因导致的骨髓再生障碍患者血液学支持治疗的效果。
